Ticagrelor monotherapy after short duration of dual antiplatelet therapy compared to continued dual antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary interventions: an updated meta-analysis

被引:0
|
作者
Mansuri, Zeeshan [1 ]
Ashraf, Hadiah [2 ]
Taikadan, Thahsin [3 ]
Rajith, Gokul [4 ]
Ayesha, Ayesha [5 ]
Fatima, Urooj [6 ]
Erzinger, Gabriel [7 ]
机构
[1] GCS Med Coll & Res Ctr, Dept Cardiol, Opp DRM Off,Naroda Rd, Ahmadabad 380025, Gujarat, India
[2] Rawalpindi Med Univ, Rawalpindi, Pakistan
[3] Calicut Med Coll, Kozhikode, India
[4] All India Inst Med Sci, Gauhati, India
[5] Shifa Coll Med, Islamabad, Pakistan
[6] Jinnah Sindh Med Univ, Karachi, Pakistan
[7] Univ Joinville Reg UNIVILLE, Joinville, Brazil
关键词
dual anti-platelet therapy; percutaneous coronary intervention; ticagrelor; ASPIRIN;
D O I
10.1097/MCA.0000000000001417
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The optimum duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) in patients with acute coronary syndromes (ACS) remains controversial. Ticagrelor monotherapy after short duration of DAPT (1-3 months) is a subject of research. We conducted an updated systematic review and meta-analysis comparing the ticagrelor monotherapy with continued DAPT after short duration of DAPT in patients with ACS undergoing PCI. Methods PubMed, Embase, and Cochrane databases were searched for studies comparing ticagrelor monotherapy to DAPT after PCI and reported the outcomes of major adverse cardiovascular and cerebrovascular events (MACCE); net adverse clinical events (NACE); myocardial infarction (MI); major bleeding; death from any cause; definite or probable stent thrombosis; and target vessel revascularization (TVR). Data were extracted from published reports and quality assessment was performed per Cochrane recommendations. Statistical analysis was performed using Review Manager (Cochrane collaboration). Heterogeneity was examined with I-2 test. Results Of 3,208 results, five studies with 21,407 patients were included of which 50% received ticagrelor monotherapy. Studies had reported follow up of 12 months. Major bleeding [hazard ratio 0.47; 95% confidence interval (CI), 0.37-0.61; P < 0.001], NACE (hazard ratio 0.71; 95% CI, 0.56-0.90; P = 0.005), and all-cause death (hazard ratio 0.76; 95% CI, 0.59-0.98; P = 0.04) were significantly less with ticagrelor monotherapy. Other outcomes were comparable in both groups. Conclusion In patients with ACS undergoing PCI, ticagrelor monotherapy reduces major bleeding, NACE and all-cause death as compared to continued DAPT for 12 months. Major ischemic outcomes were similar. Ticagrelor monotherapy is the way forward after short duration of DAPT after PCI in ACS.
引用
收藏
页码:590 / 597
页数:8
相关论文
共 50 条
  • [21] Duration and kind of dual antiplatelet therapy for acute coronary syndrome patients: a network meta-analysis
    D'ascenzo, Fabrizio
    De Filippo, Ovidio
    Angelini, Filippo
    Piroli, Francesco
    De Lio, Giulia
    Bocchino, Pier P.
    Baldetti, Luca
    Melillo, Francesco
    Chieffo, Alaide
    Saglietto, Andrea
    Omede, Pierluigi
    Montefusco, Antonio
    Conrotto, Federico
    de Ferrari, Gaetano M.
    MINERVA CARDIOLOGY AND ANGIOLOGY, 2023, 71 (05) : 494 - 503
  • [22] P2Y12 Inhibitor Monotherapy After a Short Dual Antiplatelet Therapy Versus Standard-Term Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention: A Contemporary Meta-Analysis
    Ai-Chen Ho
    Ugochukwu Egolum
    Shanea Parker
    Jordan Dimmel
    Andrew Hawkins
    Hua Ling
    Clinical Drug Investigation, 2020, 40 : 799 - 808
  • [23] Individualizing Duration of Dual Antiplatelet Therapy After Acute Coronary Syndrome or Percutaneous Coronary Intervention
    Bagai, Akshay
    Bhatt, Deepak L.
    Eikelboom, John W.
    Mancini, G. B. John
    Cohen, Eric A.
    Vijayaraghavan, Ram
    Cheema, Asim N.
    Udell, Jacob A.
    Niznick, Joel
    Tanguay, Jean-Francois
    Verma, Subodh
    Mehta, Shamir R.
    CIRCULATION, 2016, 133 (21) : 2094 - 2098
  • [24] P2Y12 INHIBITOR MONOTHERAPY AFTER A SHORT DUAL ANTIPLATELET THERAPY VS. 12-MONTH DUAL ANTIPLATELET THERAPY IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: A META-ANALYSIS
    Ling, Hua
    Egolum, Ugochukwu
    Parker, Shanea
    Ho, Ai-Chen
    Dimmel, Jordan
    Hawkins, Andrew
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (11) : 73 - 73
  • [25] P2Y12 Inhibitor Monotherapy After a Short Dual Antiplatelet Therapy Versus Standard-Term Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention: A Contemporary Meta-Analysis
    Ho, Ai-Chen
    Egolum, Ugochukwu
    Parker, Shanea
    Dimmel, Jordan
    Hawkins, Andrew
    Ling, Hua
    CLINICAL DRUG INVESTIGATION, 2020, 40 (09) : 799 - 808
  • [26] Duration of dual antiplatelet therapy and outcome in patients with acute coronary syndrome undergoing percutaneous revascularization: A meta-analysis of 11 randomized trials
    Verdoia, Monica
    Khedi, Elvin
    Ceccon, Claudia
    Suryapranata, Harry
    De Luca, Giuseppe
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2018, 264 : 30 - 38
  • [27] Dual Antiplatelet Therapy for Three Months Followed by Monotherapy is Non-inferior to One Year Dual Antiplatelet Therapy in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention-A Systematic Review and Meta-Analysis
    Anwar, Muhammad Fazeel
    Khan, Behram A.
    Hassan, Syeda Fatima
    Nasreen, Sarwat
    Malik, Saad Ullah
    Fazeel, Hafiz Muhammad
    Din, Asim Tameez Ud
    Chung, Jacqueliene
    Mirza, Mohsin
    CIRCULATION, 2019, 140
  • [28] ORAL ANTICOAGULANTS WITH DUAL VERSUS SINGLE ANTIPLATELET THERAPY IN PATIENTS AFTER PERCUTANEOUS CORONARY INTERVENTION: AN UPDATED META-ANALYSIS
    Briasoulis, Alexandros
    Androulakis, Emmanuel
    Papageorgiou, Nikolaos
    Zacharia, Effimia
    Palla, Mohan
    Charakida, Marietta
    Mallikethi-Reddy, Sagar
    Siasos, Gerasimos
    Toutouzas, Konstantinos
    Afonso, Luis
    Tousoulis, Dimitris
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 67 (13) : 453 - 453
  • [29] Dual antiplatelet therapy after percutaneous coronary intervention: Personalize the duration
    Howard, Travis M.
    Khot, Umesh N.
    CLEVELAND CLINIC JOURNAL OF MEDICINE, 2021, 88 (06) : 325 - 332
  • [30] Triple versus dual antiplatelet therapy for coronary heart disease patients undergoing percutaneous coronary intervention: A meta-analysis
    Zhou, Hong
    Feng, Xiao-Ling
    Zhang, Hong-Ying
    Xu, Fei-Fei
    Zhu, Jie
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2013, 6 (04) : 1034 - 1040